FDA Approved First Oral PCSK9 Inhibitor

The drug Lipfendra provides a new treatment option for adults with high LDL cholesterol through daily oral medication.

Updated on Oct. 5, 2026 in Heart Disease

Bold flat-color editorial illustration of abstract geometric protein structures, representing the biological mechanism of the new cholesterol medication. — The FDA has approved enlicitide, sold as Lipfendra, providing the first oral PCSK9-inhibitor option for adults struggling to manage high LDL cholesterol levels. AI Illustration. Upload story photo >

Live Poll

Would you prefer a daily pill over regular injections to manage your cholesterol levels?

The FDA has approved enlicitide, sold as Lipfendra, as the first oral PCSK9-inhibitor for adults with high LDL cholesterol. The medication offers a daily pill alternative for patients, including those with familial hypercholesterolemia, who require cholesterol management.

Why it matters

Enlicitide provides a cholesterol-lowering treatment option for patients who prefer pills over traditional injectable medications. This development offers a new pathway for patients to reach target LDL levels when standard statins alone are insufficient.

In clinical trials, patients taking 20mg of enlicitide daily saw average LDL levels drop from 95 mg/dL to 39 mg/dL over 24 weeks. Approximately two-thirds of participants reached an LDL level below the 55 mg/dL target for high-risk patients.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.

UT Southwestern Medical Center

This academic medical center served as a site for the clinical research and leadership involved in the development of enlicitide.

The details

Enlicitide works by binding to the PCSK9 protein, which prevents the protein from attaching to LDL receptors and effectively increases the number of receptors available to clear cholesterol from the blood. While 97% of participants in the trial were already taking statins, the addition of the new medication resulted in significant further reductions in LDL levels.

The FDA first approved PCSK9-inhibitor injectable drugs in 2015.
Medical associations published new cholesterol management guidelines in March 2026.
Clinical trial participants recorded LDL reductions after a 24-week period.
The total duration of the enlicitide clinical trial spanned 52 weeks.

The Big Picture

This development follows the precedent set by the 2015 approval of injectable PCSK9-inhibitors, marking a transition toward more convenient oral delivery systems for the same therapeutic mechanism.

Patients who previously struggled with the inconvenience of injectable cholesterol medication may now be able to manage their condition with a daily pill. Individuals should consult their physicians to determine if this new treatment option is appropriate for their specific health needs.

The takeaway

The arrival of an oral PCSK9-inhibitor represents a shift in how high-risk patients may approach daily cholesterol management. Patients and providers should note that while LDL levels decrease significantly, the impact of this drug on preventing major cardiovascular events remains under study.

What happens next

Researchers are currently conducting ongoing studies to determine whether the use of enlicitide effectively lowers the long-term incidence of heart attacks and strokes.